Aurobindo Pharma Shares Dip on Weak Outlook

  Published 10 months ago

Aurobindo Pharma shares fell over 2% after reporting a slight Q4 profit dip and forecasting flat FY26 margins. Concerns center around Revlimid competition, plant delays, and subsequent analyst downgrades and lowered estimates.

  • Q4 profit declined; FY26 margins flat.
  • Revlimid sales are expected to decrease.
  • Analysts cut price targets & downgraded.

You might like these

Hathway Q1 PBT Surges 59%

India Govt Security Re‑issue Auction 2025

Banks Cautious Ahead of RBI VRRR

Hero MotoCorp Q1 Profit Beats Forecasts

RBI Profits Surge to $31.4 Billion

GMM Pfaudler: Poland Expansion Boosts Shares

Aurobindo Pharma Faces USFDA Observations

News that matters the most ⚡